Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | LA |
Nausea/s "still beyond nauseous; Fatigue/s severe fatigue; This non-serious case was reported by a consumer via call center representative and described the occurrence of nausea in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. The patient's past medical history included vitiligo (autoimmune diseases), lymphedema (autoimmune diseases) and shingles (diagnosed with shingles in MAY-2025). Previously administered products included Shingrix (1st dose received on unknown date). On 04-MAR-2026, the patient received the 2nd dose of Shingrix (left arm). On 05-MAR-2026, 1 days after receiving Shingrix, the patient experienced nausea (Verbatim: Nausea/s "still beyond nauseous) and fatigue (Verbatim: Fatigue/s severe fatigue). The outcome of the nausea and fatigue were not resolved. The reporter considered the nausea and fatigue to be unrelated to Shingrix. The company considered the nausea and fatigue to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 09-MAR-2026 The batch number was not provided, and we are unable to contact the reporter. Follow up information was received on 09-MAR-2026. The patient reported she was still beyond nauseous and had severe fatigue on 9-MAR-2026 after receiving the second dose on 4-MAR-2026. Summary of changes: Updated product tab, event tab and narrative.
Medical History/Concurrent Conditions: Lymphedema (autoimmune diseases); Shingles (diagnosed with shingles in MAY-2025); Vitiligo (autoimmune diseases)